The collaboration between ten23 health and BD aims to commercialize the BD Libertas wearable injector for large-volume ...
Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease ...
Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...
TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...
On Feb. 14, the agency approved the drug, a biosimilar to Novolog, for glycemic control improvement in adult and pediatric diabetic patients. The subcutaneous medication is approved in a 3 milliliter, ...
Researchers will highlight new injection systems, wearable devices and testing services supporting high-viscosity biologics, ...
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results